COMMUNIQUÉS West-GlobeNewswire

NewBiologix Licenses Xcell-Eng-HEK293 Cell Line to ReciBioPharm for Development and Manufacture of Adeno-Associated Virus (AAV) Therapeutics
08/05/2025
Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines for advanced therapies Complements and further expands ReciBioPharm’s AAV offering Achieves industry-leading results across [...]
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
08/05/2025
Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute [...]
Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.
08/05/2025
May 8, 2025 Announcement no. 15 Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. Interim results and a business update for the first [...]
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook
08/05/2025
COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains [...]
Swarm Oncology to present at Bio€quity Europe 2025
08/05/2025
London, U.K., May 8 2025 , Swarm Oncology Ltd. (“Swarm Oncology” or “the Company”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, today [...]
Interim report Q1 2025
08/05/2025
Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: “ We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. [...]
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update
08/05/2025
Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first quarter 2025 results [...]
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC [...]
Zealand Pharma Announces Financial Results for the First Three Months of 2025
08/05/2025
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and [...]
Pharming Group reports first quarter 2025 financial results and provides business update
08/05/2025
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued [...]
Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA
08/05/2025
Milan, ITALY – 8 May 2025 – Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces an upcoming oral presentation showcasing [...]
Vancouver-Based Delfi Medical Innovations Takes Blood Flow Restriction Technology to New Heights — Literally
08/05/2025
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Delfi Medical Innovations Inc., a global leader in blood flow restriction (BFR) technology based in Vancouver, is proud to announce that its equipment has [...]
Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
07/05/2025
Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in fellow eyes [...]
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
07/05/2025
Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public Offering MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “ [...]
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
07/05/2025
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra- [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05/2025
CLEVELAND, May 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
Viemed Healthcare Announces First Quarter 2025 Financial Results
07/05/2025
LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced [...]
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07/05/2025
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first quarter of 2025 reached [...]
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07/05/2025
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first quarter of 2025 reached [...]

Pages